Table 1.

Clinical characteristics of 347 patients with CDK4/6, CDKN2A/B aberrations (univariate analysis)

Patient characteristics (N = 347)	Aberrant CDK4/6, DKN2A/B N = 79 (%)	Normal CDK4/6, CDKN2A/B N = 268 (%)	P-value*
Gender			0.026
Women (N = 196)	36 (18.4%)	160 (81.6%)
Men (N = 151)	43 (28.5%)	108 (71.5%)
Age at diagnosis			0.13
Age ≥ 50 y (N = 212)	54 (25.5%)	158 (74.5%)
Age <50 y (N = 135)	25 (18.5%)	110 (81.5%)
Types of cancer diagnosis§
Breast (N = 74)	7 (9.5%)	67 (90.5%)	0.0021
Glioblastoma (N = 26)	21 (80.8%)	5 (19.2%)	< 0.0001
Colorectal (N = 26)	0 (0%)	26 (100%)	0.004
Lung (N = 23)	6 (26.1%)	17 (73.9%)	0.69
Melanoma (N = 23)	8 (34.8%)	15 (65.2%)	0.16
Appendix (N = 20)	1 (5.0%)	19 (95.0%)	0.27
Site of metastasis (N = 280)	Aberrant CDK4/6, DKN2A/B N = 50 (%)	Normal CDK4/6, CDKN2A/B N = 230 (%)
Lymph node metastasis			0.73
Yes (N = 145)	27 (18.6%)	118 (81.4%)
No (N = 135)	23 (17.0%)	112 (83.0%)
Liver metastasis			0.74
Yes (N = 101)	17 (16.8%)	84 (83.2%)
No (N = 179)	33 (18.4%)	146 (81.6%)
Bone metastasis			0.36
Yes (N = 82)	12 (14.6%)	70 (85.4%)
No (N = 198)	38 (19.2%)	160 (80.8%)
Lung metastasis			0.23
Yes (N = 81)	11 (13.6%)	70 (86.4%)
No (N = 199)	39 (19.6%)	160 (80.4%)
Omentum/Peritoneum metastasis			0.92
Yes (N = 49)	9 (18.4%)	40 (81.6%)
No (N = 231)	41(17.8%)	190 (82.2%)
Brain metastasis			0.16
Yes (N = 34)	9 (26.5%)	25 (73.5%)
No (N = 246)	41(16.7%)	205 (83.3%)
Soft tissue metastasis			0.21
Yes (N = 31)	3 (9.7%)	28 (90.3%)
No (N = 249)	47 (18.9%)	202 (81.1%)
Adrenal metastasis			0.51
Yes (N = 12)	3 (25.0%)	9 (75.0%)
No (N = 268)	47 (17.5%)	221 (82.5%)
Site of biopsies			0.83
Primary (N = 125)	23 (18.4%)	102 (81.6%)
Metastases (N = 155)	27 (17.4%)	128 (82.6%)

^* P-values are from Fisher's exact test.

^§ Included characteristics with N ≥ 20 of primary cancer diagnosis. See Table S1 for complete list of characteristics with N < 20.

^¶ Excluded patients with hematological malignancy (N = 21) and CNS tumors (N = 46). Reported here with site of metastasis with N ≥ 10.